B. Massidda

3.5k total citations
84 papers, 2.3k citations indexed

About

B. Massidda is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, B. Massidda has authored 84 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 60 papers in Oncology, 27 papers in Pulmonary and Respiratory Medicine and 22 papers in Cancer Research. Recurrent topics in B. Massidda's work include Cancer Treatment and Pharmacology (35 papers), Colorectal Cancer Treatments and Studies (23 papers) and Breast Cancer Treatment Studies (14 papers). B. Massidda is often cited by papers focused on Cancer Treatment and Pharmacology (35 papers), Colorectal Cancer Treatments and Studies (23 papers) and Breast Cancer Treatment Studies (14 papers). B. Massidda collaborates with scholars based in Italy, United States and United Kingdom. B. Massidda's co-authors include Pasquale Comella, G. Frasci, Giuseppe Comella, Franco Buzzi, G.P. Nicolella, M Belli, Nicola Panza, Mario De Lena, A. Rubagotti and Francesco Boccardo and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and British Journal of Cancer.

In The Last Decade

B. Massidda

83 papers receiving 2.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
B. Massidda Italy 23 1.6k 848 662 507 302 84 2.3k
Massimo Lopez Italy 21 1.6k 1.0× 598 0.7× 516 0.8× 207 0.4× 405 1.3× 59 2.2k
Giorgio Cocconi Italy 25 1.4k 0.9× 769 0.9× 421 0.6× 223 0.4× 431 1.4× 85 2.2k
D. Amoroso Italy 23 2.0k 1.2× 791 0.9× 925 1.4× 668 1.3× 455 1.5× 104 2.8k
Edda Simoncini Italy 26 1.7k 1.1× 753 0.9× 1.1k 1.6× 360 0.7× 440 1.5× 99 2.5k
W. Kwasny Austria 27 2.4k 1.5× 727 0.9× 1.9k 2.9× 1.2k 2.3× 584 1.9× 56 3.5k
Stig B. Holmberg Sweden 20 1.4k 0.8× 564 0.7× 1.3k 2.0× 275 0.5× 244 0.8× 51 2.3k
Kjell M. Tveit Norway 30 1.6k 1.0× 526 0.6× 437 0.7× 246 0.5× 642 2.1× 79 2.8k
Nils‐Olof Bengtsson Sweden 19 1.1k 0.7× 382 0.5× 763 1.2× 230 0.5× 436 1.4× 35 2.0k
Hans‐Joachim Lück Germany 28 1.9k 1.2× 572 0.7× 721 1.1× 182 0.4× 395 1.3× 67 2.9k
Simon Thézenas France 29 1.7k 1.0× 786 0.9× 723 1.1× 153 0.3× 830 2.7× 117 3.0k

Countries citing papers authored by B. Massidda

Since Specialization
Citations

This map shows the geographic impact of B. Massidda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by B. Massidda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites B. Massidda more than expected).

Fields of papers citing papers by B. Massidda

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by B. Massidda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by B. Massidda. The network helps show where B. Massidda may publish in the future.

Co-authorship network of co-authors of B. Massidda

This figure shows the co-authorship network connecting the top 25 collaborators of B. Massidda. A scholar is included among the top collaborators of B. Massidda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with B. Massidda. B. Massidda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Formica, Vincenzo, Rossana Casaretti, Giuseppe Comella, et al.. (2017). The panitumumab with FOLFOX4 in metastatic gastric or gastroesophageal junction adenocarcinoma (mGA) - VEGA trial. Efficacy and safety outcomes of a phase II S.I.C.O.G. study. Annals of Oncology. 28. iii40–iii40. 1 indexed citations
2.
Graziano, Francesco, Annamaria Ruzzo, Eliana Rulli, et al.. (2016). Dihydropyrimidine dehydrogenase (DPYD) gene polymorphisms profiling in colon cancer patients treated with adjuvant chemotherapy in the randomized phase III TOSCA trial. Annals of Oncology. 27. iv1–iv1. 1 indexed citations
3.
Roila, Fausto, Benedetta Ruggeri, Enzo Ballatori, et al.. (2015). Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: a randomized, double-blind study. Annals of Oncology. 26(6). 1248–1253. 24 indexed citations
4.
Palomba, Grazia, Francesco Atzori, Mario Budroni, et al.. (2014). ERCC1 polymorphisms as prognostic markers in T4 breast cancer patients treated with platinum-based chemotherapy. Journal of Translational Medicine. 12(1). 272–272. 7 indexed citations
5.
Daponte, Antonio, Simona Signoriello, Luigi Maiorino, et al.. (2013). Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma. Journal of Translational Medicine. 11(1). 38–38. 23 indexed citations
6.
Piras, Franca, Maria Teresa Perra, Francesco Atzori, et al.. (2011). Nestin expression associates with poor prognosis and triple negative phenotype in locally advanced (T4) breast cancer. European Journal of Histochemistry. 55(4). e39–e39. 36 indexed citations
7.
8.
Massidda, B., Maria Cristina Sini, Mario Budroni, et al.. (2010). Molecular alterations in key-regulator genes among patients with T4 breast carcinoma. BMC Cancer. 10(1). 458–458. 10 indexed citations
9.
Ionta, Maria Teresa, Francesco Atzori, & B. Massidda. (2010). Inflammatory breast cancer in Italy. Cancer. 116(S11). 2736–2740. 5 indexed citations
10.
Ionta, Maria Teresa, Francesco Atzori, Valeria Pusceddu, et al.. (2009). Long-Term Outcomes in Stage IIIB Breast Cancer Patients Who Achieved Less Than a Pathological Complete Response (<pCR) After Primary Chemotherapy. The Oncologist. 14(11). 1051–1060. 3 indexed citations
11.
Bartolomeo, Maria Di, Roberto Buzzoni, Luigi Mariani, et al.. (2006). Feasibility of Sequential Therapy with FOLFIRI Followed by Docetaxel/Cisplatin in Patients with Radically Resected Gastric Adenocarcinoma. Oncology. 71(5-6). 341–346. 11 indexed citations
12.
13.
Palmeri, S., Vito Lorusso, Laura Palmeri, et al.. (2006). Cisplatin and gemcitabine with either vinorelbine or paclitaxel in the treatment of carcinomas of unknown primary site. Cancer. 107(12). 2898–2905. 34 indexed citations
14.
Boccardo, Francesco, A. Rubagotti, Pamela Guglielmini, et al.. (2006). Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. Annals of Oncology. 17(7). vii10–vii14. 158 indexed citations
15.
Comella, P., B. Massidda, S. Palmeri, et al.. (2005). Biweekly oxaliplatin combined with oral capecitabine (OXXEL regimen) as first-line treatment of metastatic colorectal cancer patients: a Southern Italy Cooperative Oncology Group phase II study. Cancer Chemotherapy and Pharmacology. 56(5). 481–486. 8 indexed citations
16.
Costanzo, Francesco Di, Paolo Carlini, Laura Doni, et al.. (2005). Gemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: a randomised phase II trial of the Italian oncology group for clinical research (GOIRC). British Journal of Cancer. 93(2). 185–189. 78 indexed citations
17.
18.
Frasci, G., Nicola Panza, Pasquale Comella, et al.. (1999). Cisplatin, Gemcitabine, and Paclitaxel in Locally Advanced or Metastatic Non–Small-Cell Lung Cancer: A Phase I-II Study. Journal of Clinical Oncology. 17(8). 2316–2316. 48 indexed citations
19.
Boccardo, Francesco, A. Rubagotti, D. Amoroso, et al.. (1999). Endocrinological and clinical evaluation of two depot formulations of leuprolide acetate in pre- and perimenopausal breast cancer patients. Cancer Chemotherapy and Pharmacology. 43(6). 461–466. 20 indexed citations
20.
Massidda, B. & Maria Teresa Ionta. (1996). Prevention of Delayed Emesis by a Single Intravenous Bolus Dose of 5-HT3-Receptor- Antagonist in Moderately Emetogenic Chemotherapy. Journal of Chemotherapy. 8(3). 237–242. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Massimo Lopez Breakdown of academic impact, for papers by Giorgio Cocconi Breakdown of academic impact, for papers by D. Amoroso Breakdown of academic impact, for papers by Edda Simoncini Breakdown of academic impact, for papers by W. Kwasny Breakdown of academic impact, for papers by Stig B. Holmberg Breakdown of academic impact, for papers by Kjell M. Tveit Breakdown of academic impact, for papers by Nils‐Olof Bengtsson Breakdown of academic impact, for papers by Hans‐Joachim Lück Breakdown of academic impact, for papers by Simon Thézenas
Rankless by CCL
2026